ArticleScientific reports2020
Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature.Frontiers in immunology · 2023Pooled it
- Serological and transcriptomic response of African fruit bats to immune challenge with recombinant vaccines expressing Ebola or Nipah virus antigens.Royal Society open science · 2026Article
- Programmable antibody-based chimeric entry receptors for sarbecoviruses.Communications biology · 2026Article
- Griffithsin-mediated inhibition of cellular entry of hemorrhagic fever viruses and insights into its mechanisms.Journal of virology · 2026Article
- Adjuvanted influenza vaccination increases pre-existing H5N1 cross-reactive antibodies.Nature communications · 2026Article
- A system to rapidly develop a bunyavirus pseudotyped virus neutralisation assay for pandemic preparedness.NPJ vaccines · 2025Article
- Comparison of the biological properties of bat-derived filovirus envelope glycoproteins.Journal of virology · 2025Article
- Reproducible generation of Nipah virus pseudovirions with uniform incorporation of F and G surface glycoproteins for high-throughput neutralization assays.BMC microbiology · 2025Article
- Exploring the Use of Viral Vectors Pseudotyped with Viral Glycoproteins as Tools to Study Antibody-Mediated Neutralizing Activity.Microorganisms · 2025Review
- Article
- Why implementation gaps could undermine synthetic nucleic acid oversight.Frontiers in bioengineering and biotechnology · 2025Article
- Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies.Pharmaceutics · 2023Review
- Pseudotyped Viruses for Marburgvirus and Ebolavirus.Advances in experimental medicine and biology · 2023Article
- Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application.Pathogens (Basel, Switzerland) · 2021Review
- Cross-Neutralisation of Novel Bombali Virus by Ebola Virus Antibodies and Convalescent Plasma Using an Optimised Pseudotype-Based Neutralisation Assay.Tropical medicine and infectious disease · 2021Article
- Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays.Nature protocols · 2021Article
- More Than Just Gene Therapy Vectors: Lentiviral Vector Pseudotypes for Serological Investigation.Viruses · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ebola virus (EBOV) is an enveloped, single-stranded RNA virus that can cause Ebola virus disease (EVD). It is thought that EVD survivors are protected against subsequent infection with EBOV and that neutralising antibodies to the viral surface glycoprotein (GP) are potential correlates of protection. Serological studies are vital to assess neutralising antibodies targeted to EBOV GP; however, handling of EBOV is limited to containment level 4 laboratories. Pseudotyped viruses can be used as alternatives to live viruses, which require high levels of bio-containment, in serological and viral entry assays. However, neutralisation capacity can differ among pseudotyped virus platforms. We evaluated the suitability of EBOV GP pseudotyped human immunodeficiency virus type 1 (HIV-1) and vesicular stomatitis virus (VSV) to measure the neutralising ability of plasma from EVD survivors, when compared to results from a live EBOV neutralisation assay. The sensitivity, specificity and correlation with live EBOV neutralisation were greater for the VSV-based pseudotyped virus system, which is particularly important when evaluating EBOV vaccine responses and immuno-therapeutics. Therefore, the EBOV GP pseudotyped VSV neutralisation assay reported here could be used to provide a better understanding of the putative correlates of protection against EBOV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.